Current Urology Reports

, 17:35 | Cite as

Prostate Cancer Prevention: Concepts and Clinical Trials

  • Zachary Hamilton
  • J. Kellogg ParsonsEmail author
Prostate Cancer (A Kibel, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Prostate Cancer


Prevention is an important treatment strategy for diminishing prostate cancer morbidity and mortality and is applicable to both early- and late-stage disease. There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhibitors (5-ARIs) should be considered in selected men to prevent incident prostate cancer. Level I evidence also supports the consideration of dutasteride, a 5-ARI, for tertiary prevention in active surveillance and biochemical recurrence patients. Vitamins and supplements, including selenium or vitamin E, have not been proven in clinical trials to prevent prostate cancer and in the case of Vitamin E has been found to increase the risk of incident prostate cancer. Ongoing and future trials may further elucidate the role of diet and immunotherapy for prevention of prostate cancer.


Prostate cancer 5-Alpha reductase inhibitors Immunotherapy 


Compliance with Ethical Standards

Conflict of Interest

Zachary Hamilton and J. Kellogg Parsons each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Tao ZQ, Shi AM, Wang KX, Zhang WD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015;19(5):805–12.PubMedGoogle Scholar
  3. 3.
    Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013;23:331–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Moyer VA. U.S. Preventive Services Task Force. screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Silberstein JL, Parsons JK. Prostate cancer prevention: concepts and clinical recommendations. Prostate Cancer Prostatic Dis. 2010;13(4):300–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, et al. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene. 2005;24:5868–77.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate. 2006;66:1070–5.CrossRefPubMedGoogle Scholar
  9. 9.
    van den Brandt PA, Zeegers MPA, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2003;12:866–71.PubMedGoogle Scholar
  10. 10.
    Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8:893–9.PubMedGoogle Scholar
  12. 12.
    Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006;98:245–54.CrossRefPubMedGoogle Scholar
  13. 13.•
    Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51. This was a phase III trial with over 35,000 men examining natural substances (selenium and vitamin E) for chemoprevention of prostate cancer. After 7 years of follow up, no significant benefit was seen for either substance. With additional follow up, there was a small but significantly increased risk of prostate cancer in the vitamin E group. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Klein EA, Thompson Jr IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stevens VL, McCullough ML, Diver WR, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control. 2005;16(6):643–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301:52–62.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol. 2008;53:244–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology. 1995;136:741–8.PubMedGoogle Scholar
  19. 19.•
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24. This was a phase III trial evaluating the use of finasteride for prevention of prostate cancer over a 7 year follow up period. Over 18,000 men (at least 55 years old, PSA ≤ 3 ng/ml, normal DRE) were enrolled with for-cause biopsy or end-of-study biopsy performed. There was a 25 % relative risk reduction in prostate cancer detection associated with finasteride, although higher grade disease was diagnosed more frequently in the finasteride cohort. CrossRefPubMedGoogle Scholar
  20. 20.
    Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Mellon JK. The finasteride Prostate Cancer Prevention Trial (PCPT) – what have we learned? Eur J Cancer. 2005;41:2016–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10:149–54.CrossRefPubMedGoogle Scholar
  23. 23.•
    Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202. This was a phase III trial evaluating the use of dutasteride for prevention of prostate cancer over a 4 year period. 8000 men (50–75 years old, PSA 2.5–10 ng/ml, negative prostate biopsy within 6 months of enrollment) were screened every 6 months with for-cause biopsy or planned biopsy at 2 and 4 years performed. There was a 23 % relative risk reduction associated with dutasteride and an increased incidence of high grade disease in the dutasteride cohort. This confirmed the findings of the PCPT trial. CrossRefPubMedGoogle Scholar
  24. 24.
    Lacy JM, Kyprianou N. A tale of two trials: the impact of 5α-reductase inhibition on prostate cancer (review). Oncol Lett. 2014;8(4):1391–6.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(2):97–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim J, Amos CI, Logothetis C. 5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(24):2340.CrossRefPubMedGoogle Scholar
  27. 27.
    Welch HG, Gorski DH, Albertsen PC. Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med. 2015;373(18):1685–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167–72.PubMedGoogle Scholar
  29. 29.
    Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955–63.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(9):1211–9. quiz 1219.PubMedGoogle Scholar
  32. 32.
    Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Penson DF. The pendulum of prostate cancer screening. JAMA. 2015;314(19):2031–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Schröder FH, Hugosson J, Roobol MJ. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Onc. 2010;11:725–32.CrossRefGoogle Scholar
  36. 36.
    Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Grubb RL, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008;102(11):1524–30.CrossRefPubMedGoogle Scholar
  39. 39.•
    Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103–11. This phase III trial evaluated the use of dutasteride in an active surveillance cohort, enrolling 302 men with low risk prostate cancer and following them over a 3 year period with planned biopsies performed at 1.5 and 3 years. There was a 38 % relative risk reduction in pathologic and therapeutic progression in the dutasteride cohort, although it was unclear if this was due to a true medication effect or instead due to reductions in patient/provider treatment anxiety given that dutasteride lowers PSA values and improves PSA operating characteristics. CrossRefPubMedGoogle Scholar
  40. 40.
    Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128–33.CrossRefPubMedGoogle Scholar
  41. 41.
    Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3 Pt 1):826–31. discussion 831-2.CrossRefPubMedGoogle Scholar
  42. 42.
    Schröder F, Bangma C, Angulo JC, et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol. 2013;63(5):779–87.CrossRefPubMedGoogle Scholar
  43. 43.
    Ehdaie B, Touijer KA. 5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice. Eur Urol. 2013;63(5):788–9. discussion 790-1.CrossRefPubMedGoogle Scholar
  44. 44.
    Parsons JK, Pierce JP, Mohler J, et al. A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men’s Eating and Living (MEAL) Study. Contemp Clin Trials. 2014;38(2):198–203.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Geary SM, Salem AK. Prostate cancer vaccines: update on clinical development. Oncoimmunology. 2013;2(5):e24523.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.CrossRefPubMedGoogle Scholar
  48. 48.
    Gulley JL, Heery CR, Madan RA, et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother. 2013;62(9):1521–31.CrossRefPubMedGoogle Scholar
  49. 49.
    Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol. 2009;16(5):4806–12.PubMedGoogle Scholar
  51. 51.
    Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.Google Scholar
  52. 52.
    Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol, Biomarkers Prevent: Public Am Assoc Cancer Res, Cosponsored Am Soc Prevent Oncol. 2008;17:88–94.CrossRefGoogle Scholar
  53. 53.
    Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959–68.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7:e46691.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168:250–60.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Platz EA, Tangen CM, Goodman PJ, et al. Statin drug use is not associated with prostate cancer risk in men who are regular screened. Urology. 2014;192(2):379–84.CrossRefGoogle Scholar
  57. 57.
    Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004;172:S6–11. discussion S11-12.CrossRefPubMedGoogle Scholar
  58. 58.
    Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–81.CrossRefPubMedGoogle Scholar
  59. 59.
    Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30:3540–4.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97:975–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of UrologyMoores Comprehensive Cancer Center, UC San Diego Health SystemLa JollaUSA

Personalised recommendations